Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CVL-231 on Ambulatory Blood Pressure in Schizophrenia
NCT05245539Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of emraclidine in schizophrenia (2 arms), sponsored by Cerevel Therapeutics. Primary endpoint: Mean change from Baseline to Week 8 in the 24-hour ambulatory Systolic Blood Pressure. Started Jan 2022; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05245539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245539.